about
Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicineToll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor 4Biocompatibility Assessment of Detonation Nanodiamond in Non-Human Primates and Rats Using Histological, Hematologic, and Urine Analysis.Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells.TLR agonists regulate PDGF-B production and cell proliferation through TGF-beta/type I IFN crosstalk.Nanodiamond-mitoxantrone complexes enhance drug retention in chemoresistant breast cancer cellsExosomes in Cancer Nanomedicine and Immunotherapy: Prospects and Challenges.Polyinosinic-polycytidylic acid suppresses acetaminophen-induced hepatotoxicity independent of type I interferons and toll-like receptor 3Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells.Reciprocal interaction of Wnt and RXR-α pathways in hepatocyte development and hepatocellular carcinoma.Toll-like receptors induce a phagocytic gene program through p38.A role for IRF3-dependent RXRalpha repression in hepatotoxicity associated with viral infections.Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infectionMechanisms of chemoresistance in cancer stem cells.Innate immune system regulation of nuclear hormone receptors in metabolic diseases.Type I IFNs mediate development of postinfluenza bacterial pneumonia in miceDiamond-lipid hybrids enhance chemotherapeutic tolerance and mediate tumor regression.Synthesis of nanodiamond-daunorubicin conjugates to overcome multidrug chemoresistance in leukemia.Accelerating the Translation of Nanomaterials in Biomedicine.Epigenetics in cancer stem cells.Implication of cancer stem cells in cancer drug development and drug delivery.Cancer nanomedicine: from drug delivery to imaging.Nanomedicine for global health.Nanodiamond-Manganese dual mode MRI contrast agents for enhanced liver tumor detection.E3 ligase EDD1/UBR5 is utilized by the HPV E6 oncogene to destabilize tumor suppressor TIP60.Identification and Optimization of Combinatorial Glucose Metabolism Inhibitors in Hepatocellular Carcinomas.TIP60 inhibits metastasis by ablating DNMT1-SNAIL2-driven epithelial-mesenchymal transition program.Multimodal nanodiamond drug delivery carriers for selective targeting, imaging, and enhanced chemotherapeutic efficacy.Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment.Copolymeric nanofilm platform for controlled and localized therapeutic delivery.Diamonds, Digital Health, and Drug Development: Optimizing Combinatorial Nanomedicine.Artificial Intelligence-Driven Designer Drug Combinations: From Drug Development to Personalized MedicineClinical Applications of Carbon Nanomaterials in Diagnostics and Therapy3D Culture as a Clinically Relevant Model for Personalized MedicineTriggered release of therapeutic antibodies from nanodiamond complexesOptimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)Dual-Targeting Dual-Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced Nephrotoxicity
P50
Q26776095-7400B0AD-EBCB-482A-BEAC-80C5091013EEQ28184953-D256DB1A-7C1D-4962-A7B5-72A495C53A39Q31116153-905179C4-4D37-49D8-9960-0D508333A94EQ34233172-27D44C9C-4D53-42A3-B776-D5DF5FD904EDQ34324873-035638A5-5128-462C-B7B0-63A28A300235Q34435737-48FD9342-37BF-4F7B-869D-DD6813A43500Q34554505-40ECB6AF-8EBF-4393-AF67-68662303AA19Q35011849-78E906F0-28A5-4B19-A142-F8C439C81DC7Q35100733-A0F31BB7-225A-4F68-8E2D-B611AFD8A72AQ35147588-9F110F8B-DAE6-41EB-976C-D7A002119C40Q35834699-2C63C0B2-4940-4531-A52B-55DAA9078D89Q36228100-8510999A-E4CE-4CBF-B162-6543DF5B06F4Q36402672-4CB7EB2A-E6B2-4E27-8D41-7CE44357721FQ36591484-04A1BDCB-B7F7-4DD4-AB4B-A203253B4805Q36741784-F858B56D-CB50-4AE4-8AB9-7A786B8C81AEQ37241332-26EDDFDE-F9B2-4B9B-832B-1429AB5C12FCQ37412398-6AD0B194-D9F0-4E3C-90F8-A3722207E8F0Q37549450-32D57AD3-8BFD-4AA5-AECB-0058077A05DEQ37581374-CEB0471B-4408-4AAF-9A96-87AFB76602CDQ37618640-10EFFE06-5F84-4A28-9489-83DDD8453F5AQ38034735-B4D099A2-4557-48F4-8279-0A02E613A470Q38172476-D3C5A502-1757-4D1F-A070-E67D0AA225EFQ38217978-09C43988-CFAD-445F-BD97-4A8EE0990009Q38724942-A015B488-5FA4-4617-9811-4279719D3F13Q38847256-9F87D816-CAE6-4372-A52E-2E0656AA9E97Q38893018-BC98328B-304C-483C-AAAC-AB79776189EDQ39368430-A4CC9410-5C9B-4540-8E46-8560F1C083C7Q39471154-D4E5A607-372C-4B31-BCDD-A8C93CE93476Q39578651-49AC1FD9-E73F-4A0D-A36C-A8FFDB5FD7EDQ39885372-06A3D904-77A3-46C2-8382-64ED9EC876D3Q40408745-C36DA47A-06A3-400D-A50B-F872CEB9BCD7Q62493697-9702414A-DBBE-4E46-BDAD-E7CA2C24B0D2Q62494510-13A9842F-C117-4737-A8A8-CFE4582FA0A4Q62733901-B256554B-D812-473D-A1ED-9E9445E12A0FQ62733905-9D651E3B-C9C6-42AF-9BEA-79D25FF8AED5Q90839493-67893C2C-DB9F-4BB0-BBA5-3639E47FB3BFQ92838958-DD9B9AFB-26BE-4DA1-9C09-61B665D10D4C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Edward K Chow
@ast
Edward K Chow
@en
Edward K Chow
@es
Edward K Chow
@nl
Edward K Chow
@sl
type
label
Edward K Chow
@ast
Edward K Chow
@en
Edward K Chow
@es
Edward K Chow
@nl
Edward K Chow
@sl
prefLabel
Edward K Chow
@ast
Edward K Chow
@en
Edward K Chow
@es
Edward K Chow
@nl
Edward K Chow
@sl
P106
P21
P31
P496
0000-0002-3075-1898